Lupin Limited - Company Snapshot & SWOT Analysis

Publication ID:

NAV0619014

Publication Date:

June 11, 2019

Pages:

Publisher:

NAVADHI

Countries:

India [1]

USD 200.00

Pharma & Healthcare [2]

Company Reports (Pharma & Healthcare) [3]

Description:

India pharmaceuticals market听 [4]is expected to be worth USD 33.18 billion by 2023.

The business segments of Lupin mainly comprise of APIs and Formulations, and the company manufactures and markets pharmaceutical products in all major markets across the globe. The company is the tenth largest pharmaceutical company in the world by sales. In the domestic market, Lupin has a presence in key growth therapies such as Cardiology, Central Nervous System, Diabetology, Respiratory, Gynecology, Anti-Infective, Gastro-Intestinal, and Oncology. Not unusual for a key player in India, Lupin employs market segmentation strategy along medical specialty lines to drive growth.

听

During the period of 2014-2018, the company increased its revenue from INR 111.7 bn to INR 155.60 bn, registering an average growth rate of 8.64%. In 2018 the revenue declined because of various reasons like challenges faced by US business concomitant to adverse competitive dynamics as well as regulatory hurdles limiting new launches to offset the impact.

Scope of the Lupin Limited - Company Snapshot & SWOT Analysis Report

鈥his report provides detailed information about Lupin Limited including value chain analysis, financial performance, business strategy and SWOT analysis.
鈥he report identifies the growth drivers and inhibitors for global pharmaceutical market.
鈥his report provides information about current and future trends for global pharmaceutical market.听
听

Table Of Contents:

1. Executive Summary

Scope of the Lupin Limited - Company Snapshot & SWOT Analysis Report
Research Methodology

2. Growth Drivers and Inhibitors for Global Pharmaceuticals 麻豆原创

3. Company Profile

3.1 Lupin Limited
3.1.1 Company Profile
3.1.2 Lupin Limited in Pharma Manufacturing Value Chain
3.1.3 Lupin Limited: Financial Performance
3.1.4 Lupin Limited: Business Strategy
11.6.4.1 Product Level Strategy
3.1.5 SWOT Analysis of Lupin Limited

Strengths
Weaknesses
Opportunities
Threats

4. Current and Future Trends in Pharmaceutical 麻豆原创

Orphan Drugs
Biologics and Biosimilars

Current Trends
1. Increasing Severity of Drug Price Controls
2. Greater Focus on Rare Diseases / Orphan Drugs
3. Increasing Development of Nucleic Acids as Therapeutics
4. Increasing Focus on Cell Therapy
5. Implantables (Bioelectronics) and Electroceuticals are Expected to Become Mainstream
6. Use of 3D Printing to Reduce Cost and Improve Production Efficiency of Biologics
7. Increasing Use of Big Data and Artificial Intelligence (AI) in Drug Discovery

List of Exhibits
Notes
Company Information

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.